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Editorialditorial 
Optimising Asthma Care 
The dawn of the new millennium held much promise for medi-
cine  especially for chronic disorders such as hypertension, 
diabetes mellitus and asthma. Major clinical trials had been 
published, new therapies developed and the unraveling of 
pathogenetic mechanisms had opened our minds to a mo-
lecular network tantamount to a medical revolution. The next 
quantum leap that doctors had to make was to embrace this 
knowledge and transform medical practice: instead of having 
patients   managed sub-optimally such that they remained 
diseased but rather to optimise treatment to render them “nor-
mal” - through near complete cessation of the pathological 
processes such that patients are completely asymptomatic 
and occult target organ damage nullified. This quantum step 
was not taken. 
Why? The chronic disorders mentioned above have one thing 
in common- they’re largely invisible. When, you observe a pa-
tient, you can’t “see” these diseases. Because of this, they’re 
treated inadequately and patients remain symptomatic with 
impairment of lifestyle and on-going disease progression. 
This is certainly true of asthma. Recent major surveys have 
revealed that the vast majority of asthmatics are uncontrolled. 
This is manifest by regular symptoms, impaired quality of life 
and absence from work or school. Health services continued 
to record high frequencies of emergency room visits, un-
scheduled doctor visits and hospitalization for acute severe 
asthma. With many chronic conditions, there is the recommen-
dation that we treat to target; e.g. blood pressure or HbA1c for 
diabetes. With asthma, there appeared to be no definite tar-
gets and both patient and doctor accepted that asthma would 
elicit symptoms and limitations. This realisation prompted both 
the Global Initiative for Asthma (GINA) and the SA Thoracic 
Society (SATS) to commission updated guidelines the latter 
in this issue.1 
The principal theme of these guidelines is to aim to totally 
control the disease process. Whereas previous guidelines 
had concentrated on severity grading and escalating therapy, 
the new directive is to strive for control. When achieved, pa-
tients are symptom free, sleep undisturbed, have normal lung 
function, no vocational disturbance and are at minimal risk of 
exacerbations. 
The landmark trial to explore this feasibility was the GOAL 
study: Gaining Optimal Asthma Control.  Treatment was 
increased until asthma was totally controlled- manifest by 
complete cessation of symptoms and normalization of lung 
capacity. The number achieving total control was 40% and 
another 40% achieved very good control. 
The new guidelines also put medications in perspective; 
the hallmark of asthma is airway inflammation and inhaled 
corticosteroids (ICS) remain the gold standard. This is best 
combined with a LABA (long acting â agonist) for sustained 
bronchodilatation. If patients remain symptomatic then it is 
likely that inflammation persists and the ICS dose needs to be 
increased. One can also capitalize on the synergy between 
LABA & ICS as their combined effect is equivalent to doubling 
the dose of the ICS component. We’ve also gained more ex-
perience with medication. Leukotriene modifiers and LABA 
are eschewed as monotherapy and both are recommended 
as add on therapy to ICS.
There are also some simple issues that deserve attention. One 
of the most frequently neglected aspects is inhaler technique; 
one could have the most expensive or effective medication 
but if it is not delivered to the lung adequately there will be a 
poor therapeutic outcome. The technique must be checked 
regularly and reinforced as required. Information on the need 
for ICS strengthens adherence. Combination ICS & LABA 
inhalers aid compliance tremendously as they simplify the 
therapeutic regimen.
One could have the best guidelines in the world but if there’s 
no knowledge thereof, acceptance or influence on practice 
then their utility becomes questionable. Professor Bob Mash 
discusses the concept of “Outcome Mapping” in this context 
in this issue. The SATS, Allergy Society and the National 
Asthma Education Programme (NAEP) have funded an initia-
tive called the Asthma Guideline Implementation Programme 
that will disseminate and evaluate the new guide. It will start 
in the Western Cape and is envisioned to become a national 
project.2
If successful, this project will revolutionise asthma care. Both 
doctors and patients need to shift expectations; doctors need 
to know that they can bring asthma completely under control 
and patients need to expect their care-givers to offer more; 
the most cost-effective treatment so that they are largely free 
of symptoms and lifestyle impairment. Other stakeholders 
need to be incorporated as well; therapeutic decision makers 
and funders in both the private and public sectors. Lessons 
learned will help us improve strategies and possibly translate 
them to other chronic disorders to impact positively on the 
health of the nation. 
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